NASA Officially Joins ESA's 'Dark Universe' Mission

NASA has joined the European Space Agency's (ESA's) Euclid mission, a space telescope designed to investigate the cosmological mysteries of dark matter and dark energy. Euclid will launch in 2020 and spend six years mapping the locations and measuring the shapes of as many as 2 billion galaxies spread over more than one-third of the sky. It will study the evolution of our universe, and the dark matter and dark energy that influence its evolution in ways that still are poorly understood. The telescope will launch to an orbit around the sun-Earth Lagrange point L2. The Lagrange point is a location where the gravitational pull of two large masses, the sun and Earth in this case, precisely equals the force required for a small object, such as the Euclid spacecraft, to maintain a relatively stationary position behind Earth as seen from the sun. "NASA is very proud to contribute to ESA's mission to understand one of the greatest science mysteries of our time," said John Grunsfeld, associate administrator for NASA's Science Mission Directorate at the agency's Headquarters in Washington. NASA and ESA recently signed an agreement outlining NASA's role in the project. NASA will contribute 16 state-of-the-art infrared detectors and four spare detectors for one of two science instruments planned for Euclid. "ESAs Euclid mission is designed to probe one of the most fundamental questions in modern cosmology, and we welcome NASAs contribution to this important endeavor, the most recent in a long history of cooperation in space science between our two agencies," said Alvaro Gimnez, ESAs Director of Science and Robotic Exploration. In addition, NASA has nominated three U.S. science teams totaling 40 new members for the Euclid Consortium. This is in addition to 14 U.S. scientists already supporting the mission. The Euclid Consortium is an international body of 1,000 members who will oversee development of the instruments, manage science operations and analyze data. Euclid will map the dark matter in the universe. Matter as we know it -- the atoms that make up the human body, for example -- is a fraction of the total matter in the universe. The rest, about 85 percent, is dark matter consisting of particles of an unknown type. Dark matter first was postulated in 1932, but still has not been detected directly. It is called dark matter because it does not interact with light. Dark matter interacts with ordinary matter through gravity and binds galaxies together like an invisible glue. While dark matter pulls matter together, dark energy pushes the universe apart at ever-increasing speeds. In terms of the total mass-energy content of the universe, dark energy dominates. Even less is known about dark energy than dark matter. Euclid will use two techniques to study the dark universe, both involving precise measurements of galaxies billions of light-years away. The observations will yield the best measurements yet of how the acceleration of the universe has changed over time, providing new clues about the evolution and fate of the cosmos. Euclid is an ESA mission with science instruments provided by a consortia of European institutes and with important participation from NASA. NASA's Euclid Project Office is based at NASA's Jet Propulsion Laboratory in Pasadena, Calif. JPL will contribute the infrared flight detectors for the Euclid science instrument. NASA's Goddard Space Flight Center in Greenbelt, Md., will test the infrared flight detectors prior to delivery. Three U.S. science teams will contribute to science planning and data analysis. JPL is managed by for NASA by the California Institute of Technology in Pasadena. For more information about Euclid, visit: http://www.nasa.gov/euclid , http://sci.esa.int/science-e/www/area/index.cfm?fareaid=102 and http://www.euclid-ec.org/ .

Please follow SpaceRef on Twitter and Like us on Facebook.

Follow this link:

NASA Officially Joins ESA's 'Dark Universe' Mission

NASA to Premiere New Mars Exploration Film Today

NASA is unveiling a new documentary film about the history of Mars exploration today (Jan. 23) to an audience in the Los Angeles area, and there's a chance the movie could eventually get distributed nationally.

"The Changing Face of Mars" premieres tonight at 8 p.m. PST at the California Institute of Technology's Beckman Auditorium in Pasadena. Admission is free, with seating on a first-come, first-served basis.

The 90-minute documentary, which was produced by NASA's Jet Propulsion Laboratory (JPL), chronicles humanity's efforts to explore the Red Planet, from the first flyby in 1965 by NASA's Mariner 4 probe to the current work being done on the Martian surface by the agency's car-size Curiosity rover.

Reminders of those two bookend missions will be on display at the premiere, which will feature a full-scale Curiosity replica and the historic "first image" of Mars a hand-drawn color portrait put together in 1965 using data beamed home by Mariner 4.

One aim of "The Changing Face of Mars" is to highlight and preserve the contributions of the 1960s-era pioneers, who blazed a trail to the Red Planet that engineers at NASA and other space agencies are still following today.

"They didn't know how to build a spacecraft; it had never been done before. There was no one they could turn to to ask how to build a spacecraft," said writer/director/producer Blaine Baggett, who heads JPL's office of communication and education.

"So I just have a tremendous respect and appreciation for those who came before, and I'm bound and determined to capture their memories and experiences so we have them, before they're lost for good," Baggett told SPACE.com.

"The Changing Face of Mars" is the fourth installment in Baggett's ongoing series "Beginnings of the Space Age." None of the titles are available nationally at the moment, though Baggett said discussions about a possible deal to distribute all four are underway.

Baggett hopes the series includes eight or nine films eventually.

"There are four or five more films, if I can last out and they keep me here that long," he said.

Go here to read the rest:

NASA to Premiere New Mars Exploration Film Today

NASA's Opportunity Rover Begins Year 10 on Mars

The older, smaller cousin of NASA's huge Mars rover Curiosity is quietly celebrating a big milestone today (Jan. 24) nine years on the surface of the Red Planet.

NASA's Opportunity rover landed on Mars the night of Jan. 24, 2004 PST (just after midnight EST on Jan. 25), three weeks after its twin, Spirit, touched down. Spirit stopped operating in 2010, but Opportunity is still going strong, helping scientists better understand the Red Planet's wetter, warmer past.

"No one could've imagined how good the exploration and scientific discovery would be for this vehicle, looking from the perspective of nine years ago," said John Callas, Opportunity's project manager at NASA's Jet Propulsion Laboratory in Pasadena, Calif. "It's been a phenomenal accomplishment."

The headline-stealing Curiosity rover, for its part, touched down on Aug. 5, 2012, marking the next step in Mars exploration. The car-size Curiosity weighs about 1 ton five times more than either Spirit or Opportunity.

Long-lived rovers

Spirit and Opportunity were originally supposed to spend three months searching for evidence of past water activity on the Red Planet. The golf-cart-size robots found plenty of such signs at their separate landing sites, showing that Mars was not always the cold and arid planet we know today. [Most Amazing Discoveries by Spirit and Opportunity]

For example, in 2007 Spirit uncovered an ancient hydrothermal system in Gusev Crater, suggesting that two key ingredients for life as we know it liquid water and an energy source were both present in some parts of Mars long ago.

And Opportunity is currently inspecting clay deposits along the rim of Mars' huge Endeavour Crater. Clays form in relatively neutral (as opposed to acidic or basic) water, so the area may once have been capable of supporting primitive microbial life, researchers say.

"This is our first glimpse ever at conditions on ancient Marsthat clearly show us a chemistry that would've been suitable for life at the Opportunity site," Opportunity principal investigator Steve Squyres, of Cornell University, said of the discovery at a conference last month.

The rovers rolled far beyond their 90-day warranties. Spirit finally stopped communicating with Earth in March 2010, after getting mired in soft sand and failing to maneuver into a position that would allow it to slant its solar panels toward the sun over the 2009-2010 Martian winter. NASA declared the rover dead in 2011.

Visit link:

NASA's Opportunity Rover Begins Year 10 on Mars

NASA Joins European Dark Energy Mission

NASA has officially joined the European Space Agency's Euclid mission, a space telescope that will launch in 2020 to study the mysterious dark matter and dark energy pervading the universe.

NASA will contribute 16 infrared detectors and four spares for one of the Euclid telescope's two planned science instruments, agency officials announced today (Jan. 24). NASA has also nominated 40 new members for the Euclid Consortium, an international body of 1,000 scientists that will oversee the mission and its development.

"NASA is very proud to contribute to ESA's mission to understand one of the greatest science mysteries of our time," John Grunsfeld, associate administrator for NASA's Science Mission Directorate, said in a statement.

Astronomers think the "normal" matter we can see and touch makes up just 4 percent of the universe. The rest is comprised of dark matter and dark energy strange stuff whose existence scientists infer from its influence on the 4 percent.

Dark energy is especially intriguing, since many researchers believe it to be the strange force responsible for the accelerating expansion of the universe. But just what it is remains a mystery.

The Euclid mission hopes to shine some light into the universe's darkest corners. After launching to a gravitationally stable spot called the sun-Earth Lagrange point 2, the 4,760-pound (2,160-kilogram)spacecraft will spend six years mapping and studying up to two billion galaxies throughout the universe.

Euclid's observations of these galaxies and their distribution should allow astronomers to better understand how the universe's acceleration has changed over time, revealing key insights about the nature of dark matter and dark energy, NASA officials said.

"ESA's Euclid mission is designed to probe one of the most fundamental questions in modern cosmology, and we welcome NASA's contribution to this important endeavor, the most recent in a long history of cooperation in space science between our two agencies," Alvaro Gimenez, ESA's Director of Science and Robotic Exploration, said in a statement.

The Euclid mission is slated to cost ESA 606 million euros, or $810 million at current exchange rates. NASA is considering its own dark-energy mission, the roughly $1.5 billion Wide-field Infrared Survey Telescope. If it eventually gets the official go-ahead, WFIRST is unlikely to launch before 2025, agency officials have said.

Follow SPACE.com senior writer Mike Wall on Twitter @michaeldwallor SPACE.com @Spacedotcom. We're also on FacebookandGoogle+.

Link:

NASA Joins European Dark Energy Mission

:: 24, Jan 2013 :: NEW HYDROGEL FROM THE INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY AND IBM DESTROYS SUPERBUGS AND …

New Hydrogel from the Institute of Bioengineering and Nanotechnology and IBM Destroys Superbugs and Drug-Resistant Biofilms

Novel antimicrobial hydrogel prevents antibiotic-resistant microbes from forming on wounds, medical devices and implants

Singapore, January 24, 2013 Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research today unveiled the first-ever antimicrobial hydrogel that can break apart biofilms and destroy multidrug-resistant superbugs upon contact. Tests have demonstrated the effectiveness of this novel synthetic material in eliminating various types of bacteria and fungi that are leading causes of microbial infections, and preventing them from developing antibiotic resistance. This discovery may be used in wound healing, medical device and contact lens coating, skin infection treatment and dental fillings.

IBN Executive Director Professor Jackie Y. Ying said, As a multidisciplinary research institute, IBN believes that effective solutions for complex healthcare problems can only emerge when different fields of expertise come together. Our longstanding partnership with IBM reflects the collaborative creativity across multiple platforms that we aim to foster with leading institutions and organizations. By combining IBNs biomaterials expertise and IBMs experience in polymer chemistry, we were able to pioneer the development of a new nanomaterial that can improve medical treatment and help to save lives.

Dr Yi-Yan Yang, Group Leader at IBN said, The mutations of bacteria and fungi, and misuse of antibiotics have complicated the treatment of microbial infections in recent years. Our lab is focused on developing effective antimicrobial therapy using inexpensive, biodegradable and biocompatible polymer material. With this new advance, we are able to target the most common and challenging bacterial and fungal diseases, and adapt our polymers for a broad range of applications to combat microbial infections.

In Singapore, antimicrobial drug resistance is a major healthcare problem because of the extensive use of antibiotics and medical equipment such as intravascular catheters and orthopedic implants in patients. Once in the body, these instruments become potential breeding grounds for bacterial growth. This provides a continuous source of contamination, which could result in prolonged hospitalization, higher medical costs, and greater risk of death. Research has shown that patients in Singapore with microbial infections were 10.2 times more likely to die during their hospitalization, had 4.6 times longer hospitalization, and incurred 4 times higher hospitalization cost compared to patients with no infections.

The emergence of new strains of superbugs and shortage of new drugs has exacerbated the need for an effective antimicrobial solution. Traditional household antiseptics and disinfectants are also proving to be ineffective in eliminating drug-resistant germs.

Under Dr Yang, IBN's Nanomedicine group has been conducting research on polymer and peptide nanoparticles as antimicrobial agents since 2007. Her lab has published 15 papers in high-impact factor journals such as Nature Nanotechnology, Nature Chemistry, Nano Today, Advanced Materials, ACS Nano, Biomaterials, and SMALL and filed 10 patents on their antimicrobial technologies.

Recently, Dr Yangs group and their collaborators from IBM Research co-developed a synthetic gel that is biodegradable, biocompatible and cost-effective. With over 90% water content, the hydrogel is highly flexible and easy to adapt for different uses. This gel can target the bacteria and fungi behind seven of the most common hospital-acquired infections such as MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant enterococcus), multidrug-resistant Acinetobacter baumanniiand Klebsiella pneumoniae, E. coli, Candida albicans and Cryptococcus neoformans fungi.

This new gel is comprised of the novel polymer material jointly developed by IBN and IBM Research in 2010. When mixed with water and heated to body temperature, the polymers form spontaneously into a moldable gel, due to the self-associative interactions between the polymer molecules. This allows the hydrogel to target multidrug-resistant biofilms at various parts of the body and surfaces without being flushed away. Once the antimicrobial function is activated and performed, the biodegradable gel can be naturally eliminated by the body.

Excerpt from:

:: 24, Jan 2013 :: NEW HYDROGEL FROM THE INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY AND IBM DESTROYS SUPERBUGS AND ...

Nanotechnology at UVic gets a boost into the real world

In a windowless room of a University of Victoria engineering lab, a biomedical sensor the size of a postage stamp could hold the answer to a fast and inexpensive way to diagnose disease.

Bright gold and transparent, the sensor is peppered with holes on the scale of a few hundred nanometres 600 times thinner than a human hair and infused with micro-drops of blood provided by a hospital in Toronto.

Shine a laser on the sensor and with a properly calibrated imaging camera, researchers will eventually be able to quickly detect telltale signs of leukemia and other cancers, without biopsies or laboratory blood work.

This is a proof-of-concept device. The nano-structure integrated into this biosensor looks for markers used to ID leukemia, says Alex Brolo, a UVic chemistry professor. Its not done yet, but its getting there.

This biomedical sensor and its underlying microfluid and nanotechnology are still years away from clinical use, but federal funding announced last week is designed to kick it from the basement lab in the Elliott Building to a viable prototype for industry.

The Canadian Foundation for Innovation (CFI) has committed $7.7 million for the Prometheus Project, a collaboration between UVic, Simon Fraser University, the University of British Columbia and the British Columbia Institute of Technology. It is an effort that seeks to do nothing less than make Victoria and Metro Vancouver a world-class materials science hub.

Brolo, the lead scientist for UVics arm of Prometheus, said the CFI funding will build on decade of fundamental research into nanotechnology and materials science, which has been backed by a $110 million investment.

The previous investments created a lot of proof-of-concepts, a lot of research ideas that are being tested and look promising, Brolo said. This (funding) can take us to the next level. There is a lot of competition, worldwide competition. This is a hot area with a lot of ideas, but sometimes the best idea doesnt win in the end.

UVic expects to receive about $1.8 million from the CFI and $4.5 million in total through matching provincial funds and contributions from private companies. That funding is earmarked for advanced fabricating equipment, lasers and microscopes for about 20 UVic researchers focused on solar cells, biomedical sensors and quantum computing.

For solar technology, researchers are looking to integrate nano-tubes on to a thin film to vastly improve how solar cells capture light, while also making it flexible and lighter. Nano structures integrated into biomedical sensors could not only quickly detect disease, people could use the sensors to establish a personalized baseline of health.

Continued here:

Nanotechnology at UVic gets a boost into the real world

IBM and The Institute of Bioengineering and Nanotechnology Develop New Antimicrobial Hydrogel to Fight Superbugs and …

SAN JOSE, Calif., Jan. 24, 2013 /PRNewswire/ --Researchers from IBM (NYSE: IBM) and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact. The synthetic hydrogel, which forms spontaneously when heated to body temperature, is the first-ever to be biodegradable, biocompatible and non-toxic, making it an ideal tool to combat serious health hazards facing hospital workers, visitors and patients.

(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO )

Traditionally used for disinfecting various surfaces, antimicrobials can be found in traditional household items like alcohol and bleach. However, moving from countertops to treating drug resistant skin infections or infectious diseases in the body are proving to be more challenging as conventional antibiotics become less effective and many household surface disinfectants are not suitable for biological applications.

IBM Research and its collaborators developed a remoldable synthetic antimicrobial hydrogel, comprised of more than 90% water, which, if commercialized, is ideal for applications like creams or injectable therapeutics for wound healing, implant and catheter coatings, skin infections or even orifice barriers.

Able to colonize on almost any tissue or surface, microbial biofilms - which are adhesive groupings of diseased cells present in 80% of all infections - persist at various sites in the human body, especially in association with medical equipment and devices. They contribute significantly to hospital-acquired infections, which are among the top five leading causes of death in the United States and account for up to $11 billion in healthcare spending each year.

Despite advanced sterilization and aseptic techniques, infections associated with medical devices have not been eradicated. This is due, in part, to the development of drug-resistant bacteria. According to the CDC, antibiotic drug resistance in the U.S. costs an estimated $20 billion a year in healthcare costs as well as 8 million additional days spent in the hospital.

Through the precise tailoring of polymers, researchers designed macromolecules, a molecular structure containing a large number of atoms, which combine water solubility, positive charge, and biodegradability characteristics. When mixed with water and heated to body temperature the polymers self-assemble, swelling into a synthetic gel that is easy to manipulate. This highly desirable capability stems from self-associative interactions that create a "molecular zipper" effect. Analogous to how zipper teeth link together, the short segments on the new polymers also interlock, thickening the water-based solution into re-moldable and compliant hydrogels. Since they exhibit many of the characteristics of water-soluble polymers without being freely dissolved, such materials can remain in place under physiological conditions while still demonstrating antimicrobial activity.

"This is a fundamentally different approach to fighting drug-resistant biofilms. When compared to capabilities of modern-day antibiotics and hydrogels, this new technology carries immense potential," said James Hedrick, Advanced Organic Materials Scientist, IBM Research, "This new technology is appearing at a crucial time as traditional chemical and biological techniques for dealing with drug-resistant bacteria and infectious diseases are increasingly problematic."

When applied to contaminated surfaces, the hydrogel's positive charge attracts all negatively charged microbial membranes, like powerful gravitation into a blackhole. However, unlike most antibiotics and hydrogels, which target the internal machinery of bacteria to prevent replication, this hydrogel kills bacteria by membrane disruption, precluding the emergence of any resistance.

"We were driven to develop a more effective therapy against superbugs due to the lethal threat of infection by these rapidly mutating microbes and the lack of novel antimicrobial drugs to fight them. Using the inexpensive and versatile polymer materials that we have developed jointly with IBM, we can now launch a nimble, multi-pronged attack on drug-resistant biofilms which would help to improve medical and health outcomes," said Dr Yi-Yan Yang, Group Leader, Institute of Bioengineering and Nanotechnology, Singapore.

Read the rest here:

IBM and The Institute of Bioengineering and Nanotechnology Develop New Antimicrobial Hydrogel to Fight Superbugs and ...

The World’s Largest Nanotechnology Exhibition – nano tech 2013

TOKYO--(BUSINESS WIRE)--

The nano tech Executive Committee is pleased to present nano tech 2013, the 12th International Nanotechnology Exhibition & Conference, from January 30 to February 1 at Tokyo Big Sight (Tokyo International Exhibition Center), East Exhibition Halls 4, 5, and 6 and Conference Tower.

Being held for the 12th time, the event will feature 802 booths in total by 571 companies and organizations. Of these, 235 booths will have exhibits by 221 companies and organizations from 22 countries and regions outside Japan.

Practical applications of nanotechnology are advancing, backed by the governments of individual countries. China, South Korea, Taiwan, and other Asian countries and regions have made nanotechnology into a national priority, actively supporting R&D and rapidly approaching parity with leading nanotechnology countries in the West.

[Highlights of nano tech 2013]

(1) A growing number of exhibits showing practical nanotech applications and actual products

In Japan, the influential business association Keidanren pointed to the importance of nanotechnology back in 2001. In the decade since then, R&D in the field has been funded aggressively. Now that the second nanotech decade is here, we are seeing more research aimed at achieving practical, marketable technologies in a relatively short time. Development with a clear focus on the endgame - the technological goals to be achieved and products to be realized - is being carried out actively.

(2) Large booths by all of Japans major nanotech labs

The National Institute of Advanced Industrial Science and Technology (AIST), the National Institute for Materials Science (NIMS), RIKEN, the New Energy and Industrial Technology Development Organization (NEDO) and Japans other leading research organizations will have large exhibits, where one of the attractions is being able to have technologies explained by the researchers themselves.

Much of their research is aimed at practical applications of the outstanding technology seeds emerging in the nanotechnology field. These organizations also serve to facilitate information exchange regarding cooperation by private industry, government, and academia, including component development through vertical upstream-downstream collaboration and through tie-ups across industries and across fields.

Read more from the original source:

The World’s Largest Nanotechnology Exhibition - nano tech 2013

Predictive medicine: Genes may identify potential addiction victims

Kolkata, Jan 24 (IANS) Predicting one's predisposition to addiction and warning potential victims to stay away from certain substances may become a reality in the near future, Indian scientists say.

New avenues in predictive medicine have also opened up with scientists at the Indian Institute of Chemical Biology identifying the presence of genetic mutations (or abnormal changes in the genes) responsible for addiction.

"This is a study in the area of predictive medicine. If we can identify the mutation in a gene which has association with addiction and if it's present in an individual, then we can predict that he or she is prone to addiction," Sumantra Das of the Neurobiology Division at the Indian Institute of Chemical Biology (IICB), told IANS.

IICB comes under the Council of Scientific and Industrial Research (CSIR).

Several mutations are known to exist in genes encoding certain proteins called opioid receptors through which narcotics like morphine and heroin exert their effects.

These receptors are of several classes. Two of them - mu opioid receptors (MOR) and kappa opioid receptors (KOR) - have been known to be associated with drug addiction.

While morphine, which acts through the mu opioid receptor, is widely used in controlling chronic pain, it leads to addiction in individuals in several cases.

The group of scientists had previously identified prevalence of a mutation in MOR in addicts in Kolkata. This mutation, A118G, is found in various populations all over the world.

In a recent study published in Progress in Neuro-Psychopharmacology & Biological Psychiatry Journal, the group has also identified a mutation in the KOR gene.

"KOR mutations are thought to be effective only when present with the MOR mutations," co-researcher Deepak Kumar explained.

View post:

Predictive medicine: Genes may identify potential addiction victims

Research and Markets: The Book Decision Making in Transfusion Medicine Features Causes of, and strategies to reduce …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5jb3zm/decision_making) has announced the addition of the "Decision Making in Transfusion Medicine" book to their offering.

This timely book examines the policy and clinical decisions being made today in the name of blood safety, often resulting in radical changes in transfusion medicine practice.

Although decision making in transfusion medicine is based on a wider range of inputs than solely the best research evidence, the orientation of this book remains evidence-based. In this capacity, the book is intended to serve one of the recurring principles enunciated by the FDA that decision making must be transparent. The book discusses both the evidence supporting and the hotly debated policy alternatives proposed for avoiding the risks of allogeneic blood transfusion.

Topics:

- The contrast between precautionary principle and evidence-based medicine.

- Emerging transmissible infections.

- Pathogen reduction.

- MSM donor deferrals.

- Patient blood management.

Continued here:

Research and Markets: The Book Decision Making in Transfusion Medicine Features Causes of, and strategies to reduce ...

Steven J. Kafka joins Foundation Medicine as chief business officer

By Chris Reidy, Globe Staff

Foundation Medicine Inc., a Cambridge biotechnology company using genomics data and DNA sequencing to help doctors pinpoint treatments for cancer patients, announced the appointment Wednesday of Steven J. Kafka to the newly created position of chief business officer.

Steven J. Kafka. Photo courtesy of Foundation Medicine.

Foundation Medicine is poised to expand the community of physicians, cancer centers, and pharmaceutical partners utilizing our services, Michael J. Pellini, M.D., the companys president and chief executive, said in a statement. Steve brings a valuable combination of strategic planning, financial, and operational expertise to help us drive capacity enhancements in our world-class CLIA-licensed laboratory, as well as a strong track record of building and leading successful pharmaceutical partnerships.

(CLIA stands for Clinical Laboratory Improvement Amendments in which Congress established quality standards for all laboratory testing to ensure the accuracy, reliability, and timeliness of patient test results.)

Kafka joins the company from Aileron Therapeutics, where he served as chief operating officer and chief financial officer, Foundation Medicine said in its press release.

Foundation Medicine was the subject of a recent Globe story, in part because Microsoft Corp. founder Bill Gates is an investor in the company.

Read the rest here:

Steven J. Kafka joins Foundation Medicine as chief business officer

RT Liberty: Lib’s Bouncy Time – Episode 4 – Video


RT Liberty: Lib #39;s Bouncy Time - Episode 4
Drop a like for Rt Liberties amazing episode 😀 Follow Us on Twitter: twitter.com Player: http://www.youtube.com Editor: http://www.youtube.com Song: animal collective daily routine phaseone remix ------------------------------------------------------------------------------------------------- Our Intro By: http://www.youtube.com ------------------------------------------------------------------------------------------------- Stay up to date with us: - Facebook: http://www.facebook.com - Twitter: twitter.com - Livestream: http://www.twitch.tv ------------------------------------------------------------------------------------------------- We Want To Know! VOTE poll.pollcode.com ------------------------------------------------------------------------------------------------- Submit your clips for our Top 3 and Community Videos! docs.google.com -------------------------------------------------------------------------------------------------

By: RicochetTubes

Read more from the original source:

RT Liberty: Lib's Bouncy Time - Episode 4 - Video

Liberty Hill world champion horse outjumps larger horses

by HEATHER KOVAR / KVUE News and photojournalist DOUG NAUGLE

kvue.com

Posted on January 23, 2013 at 6:23 PM

Updated yesterday at 10:13 PM

LIBERTY HILL, Texas -- The owner of High Jumpers Stable in Liberty Hill call their home "a zoo."

Leo, a triple registered stallion with four world championships, co-exists with other horses, donkeys, a young Brahma bull and a zebra, but Leo is stealing the show.

Leo is the 2011 Pinto Amateur World Jumping Champion, the 2010 Spotted Saddle Horse High Jumping Champ and the 2009 Missouri Foxtrotter World Jumping Champion. He also won more USEF jumping competitions than any other Missouri Foxtrotter or Spotted Saddle horse in history.

Lexi Ferrar has been training with the 14.3 hand horse. Ferrar said Leo continues to win even after competing against larger, 15 to 17 hand thoroughbreds.

"We went to a double a show. I rode him. He did clear a round at 3-1, and he got a blue ribbon, with all the big horses," Ferrar said.

Leo is believed to have made history with his four world championships in three breed associations.

Go here to see the original:

Liberty Hill world champion horse outjumps larger horses